Woodline Partners reports 5.4% Aligos (ALGS) stake in amended 13G

Rhea-AI Filing Summary

Aligos Therapeutics, Inc. received an updated ownership report showing that investment adviser Woodline Partners LP beneficially owns 289,169 shares of Aligos voting common stock, representing 5.4% of the class. This percentage is based on 5,353,582 shares outstanding as of October 31, 2025.

The shares are directly held by Woodline Master Fund LP, for which Woodline Partners serves as investment adviser. Woodline states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Aligos.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Aligos Therapeutics, Inc.

(Name of Issuer)

Voting Common Stock, par value $0.0001 per share

(Title of Class of Securities)

01626L204

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 01626L204

1

Names of Reporting Persons

Woodline Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 289,169.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 289,169.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

289,169.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aligos Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: One Corporate Drive, 2nd Flood, South San Francisco, CA 94080.
Item 2.
(a)	Name of person filing: This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of voting common stock, par value $0.0001 per share ("Voting Common Stock"), of Aligos Therapeutics, Inc. (the "Company") directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of the Securities Exchange Act of 1934, the beneficial owner of the shares of Voting Common Stock reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)	Citizenship: Woodline Partners is a Delaware limited partnership.
(d)	Title of class of securities: Voting Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 01626L204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 5,353,582 shares of Voting Common Stock outstanding as of October 31, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 6, 2025.
(b)	Percent of class: 5.4%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The Woodline Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the shares of Voting Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Woodline Partners LP

Signature:	/s/ Erin Mullen
Name/Title:	Erin Mullen, General Counsel & Chief Compliance Officer
Date:	02/17/2026

FAQ

What stake in Aligos Therapeutics (ALGS) does Woodline Partners report?

Woodline Partners reports beneficial ownership of 289,169 shares of Aligos Therapeutics voting common stock. This position represents 5.4% of the company’s outstanding voting common stock, based on 5,353,582 shares reported outstanding as of October 31, 2025.

What type of filing did Woodline Partners submit for Aligos Therapeutics (ALGS)?

Woodline Partners submitted an Amendment No. 3 to Schedule 13G for Aligos Therapeutics. Schedule 13G is a beneficial ownership report used by certain institutional investors holding more than five percent of a registered class of equity securities.

On what date did Woodline Partners’ Aligos (ALGS) holdings trigger this Schedule 13G/A?

The reportable event date for Woodline Partners’ Aligos holdings is December 31, 2025. That date marks when their beneficial ownership position met the conditions requiring this updated Schedule 13G/A filing under SEC rules.

How did Woodline Partners calculate its 5.4% ownership in Aligos (ALGS)?

The 5.4% ownership figure is calculated using 5,353,582 Aligos voting common shares outstanding. This outstanding share count comes from Aligos’s Form 10-Q for the quarter ended September 30, 2025, which reported shares outstanding as of October 31, 2025.

Who directly holds the Aligos (ALGS) shares reported by Woodline Partners?

The Aligos voting common stock is directly held by Woodline Master Fund LP. Woodline Partners LP, a Delaware limited partnership, acts as the investment adviser to this fund and reports beneficial ownership for regulatory purposes in the Schedule 13G/A.

Is Woodline Partners seeking to influence control of Aligos Therapeutics (ALGS)?

Woodline Partners certifies the Aligos shares were acquired and are held in the ordinary course of business. It states they were not acquired and are not held for the purpose of changing or influencing control of Aligos Therapeutics.

Who signed the Schedule 13G/A related to Aligos Therapeutics (ALGS)?

The filing was signed by Erin Mullen, identified as General Counsel and Chief Compliance Officer. The signature block certifies that the information in the statement is true, complete, and correct to the best of the signer’s knowledge and belief.